Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

223.46USD
1:27pm EDT
Change (% chg)

$-0.90 (-0.40%)
Prev Close
$224.36
Open
$224.41
Day's High
$225.04
Day's Low
$223.10
Volume
153,686
Avg. Vol
731,497
52-wk High
$261.27
52-wk Low
$184.58

Select another date:

BRIEF-Allergan announces closing of public offering

* Allergan announces closing of public offering of senior notes to refinance existing debt Source text for Eikon: Further company coverage:

BRIEF-Allergan prices public offering of senior notes to refinance existing debt

* Allergan announces pricing of public offering of senior notes to refinance existing debt

BRIEF-Allergan says VIBERZI now approved in Canada

* viberzi™ now approved in canada for patients with irritable bowel syndrome with diarrhea (ibs-d)

Several top fund managers trim Allergan stakes in first quarter

NEW YORK Six closely watched investors sliced their stakes in Allergan Plc during the first quarter, recent regulatory disclosures show, cutting what had been one of the years' best performing health stocks that has stumbled in recent days.

Several top fund managers trim Allergan stakes in 1st quarter

NEW YORK, May 15 Six closely watched investors sliced their stakes in Allergan Plc during the first quarter, recent regulatory disclosures show, cutting what had been one of the years' best performing health stocks that has stumbled in recent days.

BRIEF-Carl Icahn dissolves shared share stake in Allergan

* Carl Icahn dissolves share stake in Allergan Plc - sec filing

BRIEF-Paulson & Co Inc takes share stake in Dish Network, Monsanto

* Paulson & Co Inc takes share stake of 3.5 million shares in Dish Network Corp

BRIEF-Appaloosa LP takes share stake in CBS, cuts in Allergan

* Appaloosa lp takes share stake of 1.0 million of class b shares in cbs corp

Teva first-quarter profit tops estimates, revenue up on Actavis deal

TEL AVIV Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected fall in first-quarter profit on Thursday, with sales boosted by its $40.5 billion acquisition last year of generics drug business Actavis.

UPDATE 2-Teva Q1 profit tops estimates, revenue up on Actavis deal

* Increases Actavis synergy, cost benefit estimate by $200 mln

Select another date:

More From Around the Web